[Features of isoniazid activation in patients with tuberculosis and diabetes mellitus].
Isoniazid inactivation was studied in 60 patients with concomitant diseases (pulmonary tuberculosis and diabetes mellitus). Thirty three patients had type 1 diabetes mellitus (Group 1) and 27 had type 2 (Group 2). Weak isoniazid inactivators were 81.2% in Group 1 and 51.9% (p < 0.02), which was much greater than those in patients with tuberculosis alone. The distinctive features of isoniazid metabolism in patients with diabetes mellitus were decreased acetylation of the drug and appropriate increased splitting and oxidation. In patients with type 1 diabetes mellitus, the prevalence of weak drug inactivation may both promote higher chemotherapeutical efficiency and enhance the likelihood of side effects.
Karachunskiĭ
M A
MA
Kaminskaia
G O
GO
Kossiĭ
Iu E
IuE
Chernykh
N A
NA
D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D007538:Isoniazid
Osobennosti inaktivatsii izoniazida u bol'nykh tuberkulezom i sakharnym diabetom.